Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
840 INR | +0.21% | +1.56% | +29.38% |
Apr. 09 | Strides Pharma Science Gets US FDA Nod for Fluoxetine Tabs | MT |
Jan. 30 | Transcript : Strides Pharma Science Limited, Q3 2024 Earnings Call, Jan 30, 2024 |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+29.38% | 926M | B | ||
+19.64% | 22.41B | B+ | ||
+14.17% | 14.07B | B+ | ||
-5.84% | 12.36B | - | ||
+44.25% | 11.96B | B | ||
-3.14% | 7.49B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+9.11% | 5.3B | B+ | ||
+7.77% | 4.78B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- STAR Stock
- Ratings Strides Pharma Science Limited